Highlights

  • EBR Systems management is scheduled to present at an upcoming MedTech, Diagnostics and Digital Health forum in New York in November 2026.
  • The company is the developer of the world's only wireless cardiac pacing device currently in clinical use for heart failure patients.
  • Its patented WiSE technology eliminates the need for conventional cardiac pacing leads, which have historically been a source of complications.
  • WiSE is an investigational device in most markets and is presently available for commercial sale only in the United States.

EBR Systems, Inc. (ASX:EBR), a Silicon Valley-based cardiac technology company, has announced that its management team will present at the MedTech, Diagnostics and Digital Health and Services Industry Forum to be held at The Westin Grand Central in New York on Wednesday, 11 November 2026. The appearance reflects the company's ongoing effort to engage with industry Stakeholders as it advances its flagship wireless cardiac pacing platform through commercialisation in the United States.

Advancing Wireless Cardiac Stimulation

At the centre of EBR Systems' technology is the Wireless Stimulation Endocardially (WiSE) platform, a proprietary system designed to address a long-standing challenge in cardiac rhythm disease management. Conventional cardiac resynchronisation therapy, or CRT, requires leads threaded through blood vessels and positioned against the outer wall of the heart's left ventricle. This approach, while established, carries well-documented risks including lead displacement, perforation, and difficulty in achieving stable stimulation for some patient populations.

The WiSE system takes a different path. Rather than relying on a transvenous lead to reach the left ventricle, it uses an ultrasound-based energy transfer mechanism to wirelessly power a miniaturised implant placed inside the left ventricle itself — a location considered anatomically superior for stimulation. This implant is roughly the size of a large grain of rice, and because it is positioned endocardially, it may offer more physiologically accurate pacing for patients with heart failure requiring CRT.

The elimination of the coronary sinus lead — one of the most technically demanding elements of conventional CRT — is a key aspect of the platform's design rationale. By removing this lead from the equation, the WiSE system aims to reduce procedural complexity and the Downstream complications associated with it, while potentially expanding the pool of patients who can benefit from left ventricular stimulation.

Market Access and Regulatory Pathway

EBR Systems has been advancing its commercial strategy in the United States, where WiSE is currently available for sale. In the majority of international markets, the device remains classified as an investigational device, meaning that its broader commercial rollout is subject to ongoing regulatory evaluation and market-specific clearance pathways.

The company's ASX-traded securities take the form of CHESS Depositary Interests, or CDIs, which provide Australian-based investors with exposure to the US-incorporated entity. The CDIs are issued under Regulation S of the US Securities Act, and holders face restrictions on selling into the US market unless an applicable exemption from registration requirements applies.

As a clinical-stage company working within a complex and highly regulated segment of the medical device industry, EBR Systems' progress is shaped by the pace of clinical evidence generation and the reception of that evidence by cardiologists and hospital procurement bodies. Investor day events and industry conferences serve as an important channel through which the company can communicate its technology thesis and development trajectory to a broad audience of healthcare investors and industry participants.

Key Insights

EBR Systems occupies a differentiated position in the cardiac rhythm device space, with a technology concept that has been in active clinical development for a number of years. The upcoming conference appearance in New York provides an opportunity to articulate the platform's clinical value proposition directly to an audience of MedTech investors and healthcare professionals. For shareholders, participation in high-profile industry forums can signal ongoing engagement with potential commercial partners, distribution networks, and future clinical collaborators. The company's focus on addressing unmet need in CRT — specifically for patients for whom a coronary sinus lead approach is not feasible or has not delivered satisfactory outcomes — represents a clinically meaningful target population. Progress in commercial adoption in the US and any updates on international regulatory pathways are likely to remain key near-term themes for the company.